Tricuspid Regurgitation Etiologies Defined 03/02/26

Welcome to Cardiology Today – Recorded March 02, 2026. This episode summarizes 5 key cardiology studies on topics like loop diuretics and retrospective cohort study. Key takeaway: Tricuspid Regurgitation Etiologies Defined. Article Links: Article 1: Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 2: SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2. (Journal of cardiac failure) Article 3: Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology. (Journal of the American Heart Association) Article 4: Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. (Journal of the American Heart Association) Article 5: Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium. (Journal of the American Heart Association) Full episode page: https://podcast.explainheart.com/podcast/tricuspid-regurgitation-etiologies-defined-03-02-26/ Featured Articles Article 1: Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41765060 Summary: Patients experiencing biventricular failure or right ventricular failure after continuous-flow left ventricular assist device implantation face high mortality due to limited durable right ventricular assist device options. This study describes a hybrid ventricular assist device approach, combining a continuous-flow left ventricular assist device with a Berlin Heart EXCOR pulsatile right ventricular assist device. This therapeutic strategy addresses critical cardiogenic shock and late-onset right ventricular failure. The hybrid approach offers a novel option where conventional right-sided continuous-flow left ventricular assist devices are costly, complex, or off-label. Article 2: SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2. Journal: Journal of cardiac failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41765341 Summary: This post-hoc analysis from the CREDENCE trial investigated the efficacy and safety of S. G. L. T. two inhibitors in patients with type two diabetes and chronic kidney disease experiencing an estimated glomerular filtration rate deterioration to less than 20 milliliters per minute per 1.73 meters squared. The analysis provided crucial data to address current limitations in understanding S. G. L. T. two inhibitor use for this specific patient population. It specifically evaluated the association between decreasing estimated glomerular filtration rate and both efficacy and safety outcomes. Article 3: Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology. Journal: Journal of the American Heart Association PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757445 Summary: This multisite retrospective study provided a comprehensive classification of significant tricuspid regurgitation by its etiology, an area previously not well studied regarding survival impact. The investigation defined three distinct etiologies for tricuspid regurgitation of moderate or greater severity: primary tricuspid regurgitation due to primary valvular pathology, lead-associated tricuspid regurgitation from lead interactions, and secondary tricuspid regurgitation stemming from other causes such as right ventricular dilation. This detailed etiological categorization provides a critical framework for understanding varying survival and risk profiles among patients with this common valvular disorder. Article 4: Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. Journal: Journal of the American Heart Association PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757436 Summary: Patients with obstructive hypertrophic cardiomyopathy are known to experience adverse clinical outcomes. This retrospective cohort study systematically evaluated real-world clinical outcomes, health care resource use, and associated costs in patients with obstructive hypertrophic cardiomyopathy, specifically stratified by their sociodemographic characteristics. The research utilized a comprehensive database of U. S. adults with obstructive hypertrophic cardiomyopathy, collected between 2013 and 2021. The study demonstrated the importance of considering sociodemographic factors when assessing patient outcomes and resource utilization in this population. Article 5: Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium. Journal: Journal of the American Heart Association PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41757434 Summary: This cohort study systematically evaluated the association between initial loop diuretic dosing and outcomes in patients hospitalized for heart failure. Researchers identified and categorized initial diuretic doses, expressed in furosemide equivalents, relative to patients’ home doses across 24 hospitals. The study established length of stay as the primary outcome measured, along with secondary outcomes that included rates of acute kidney injury, in-hospital mortality, and 30-day readmission for heart failure. This research defined key endpoints for assessing optimal diuretic strategies in this hospitalized population. Transcript Today’s date is March 02, 2026. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Hybrid durable Biventricular Assist Device Implantation with Berlin Heart EXCOR Pulsatile RVAD and a Continuous Flow LVAD. Patients experiencing biventricular failure or right ventricular failure after continuous-flow left ventricular assist device implantation face high mortality due to limited durable right ventricular assist device options. This study describes a hybrid ventricular assist device approach, combining a continuous-flow left ventricular assist device with a Berlin Heart EXCOR pulsatile right ventricular assist device. This therapeutic strategy addresses critical cardiogenic shock and late-onset right ventricular failure. The hybrid approach offers a novel option where conventional right-sided continuous-flow left ventricular assist devices are costly, complex, or off-label. Article number two. SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2. This post-hoc analysis from the CREDENCE trial investigated the efficacy and safety of S. G. L. T. two inhibitors in patients with type two diabetes and chronic kidney disease experiencing an estimated glomerular filtration rate deterioration to less than 20 milliliters per minute per 1.73 meters squared. The analysis provided crucial data to address current limitations in understanding S. G. L. T. two inhibitor use for this specific patient population. It specifically evaluated the association between decreasing estimated glomerular filtration rate and both efficacy and safety outcomes. Article number three. Survival and Risk Profile of Patients With Significant Tricuspid Regurgitation by Etiology. This multisite retrospective study provided a comprehensive classification of significant tricuspid regurgitation by its etiology, an area previously not well studied regarding survival impact. The investigation defined three distinct etiologies for tricuspid regurgitation of moderate or greater severity: primary tricuspid regurgitation due to primary valvular pathology, lead-associated tricuspid regurgitation from lead interactions, and secondary tricuspid regurgitation stemming from other causes such as right ventricular dilation. This detailed etiological categorization provides a critical framework for understanding varying survival and risk profiles among patients with this common valvular disorder. Article number four. Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. Patients with obstructive hypertrophic cardiomyopathy are known to experience adverse clinical outcomes. This retrospective cohort study systematically evaluated real-world clinical outcomes, health care resource use, and associated costs in patients with obstructive hypertrophic cardiomyopathy, specifically stratified by their sociodemographic characteristics. The research utilized a comprehensive database of U. S. adults with obstructive hypertrophic cardiomyopathy, collected between 2013 and 2021. The study demonstrated the importance of considering sociodemographic factors when assessing patient outcomes and resource utilization in this population. Article number five. Cohort Study of Initial Diuretic Dosing and Outcomes Among Patients Hospitalized for Congestive Heart Failure: Insights From the Cardiovascular Quality Improvement and Care Innovation Consortium. This cohort study systematically evaluated the association between initial loop diuretic dosing and outcomes in patients hospitalized for heart failure. Researchers identified and categorized initial diuretic doses, expressed in furosemide equivalents, relative to patients’ home doses across 24 hospitals. The study established length of stay as the primary outcome measured, along with secondary outcomes that included rates of acute kidney injury, in-hospital mortality, and 30-day readmission for heart failure. This research defined key endpoints for assessing optimal diuretic strategies in this hospitalized population. Thank you for listening. Don’t forget to subscribe. Keywords loop diuretics, retrospective cohort study, S. G. L. T. two inhibitors, hospital readmission, right ventricular assist device, obstructive hypertrophic cardiomyopathy, lead-associated tricuspid regurgitation, sociodemographic characteristics, type two diabetes, chronic kidney disease, cardiogenic shock, primary tricuspid regurgitation, Berlin Heart EXCOR, biventricular failure, secondary tricuspid regurgitation, CREDENCE trial, diuretic dosing, tricuspid regurgitation, left ventricular assist device, acute kidney injury, heart failure, health care resource use, tricuspid valve disease, clinical outcomes, estimated glomerular filtration rate. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Tricuspid Regurgitation Etiologies Defined 03/02/26 first appeared on Cardiology Today.